MULTILOCUS SEQUENCE TYPING OF CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA ISOLATES FROM PATIENTS PRESENTING AT PORT ELIZABETH HOSPITALS, SOUTH AFRICA by Annear, D. et al.
Annear et al., Afr., J. Infect. Dis. (2017) 11 (2): 68-74 
https://doi.org/10.21010/ajid.v11i2.9 
 
68 
 
MULTILOCUS SEQUENCE TYPING OF CARBAPENEM RESISTANT PSEUDOMONAS 
AERUGINOSA ISOLATES FROM PATIENTS PRESENTING AT PORT ELIZABETH HOSPITALS, 
SOUTH AFRICA 
 
D. Annear1, J. Black2, 3 and S. Govender1* 
 
1Department of Biochemistry and Microbiology, Nelson Mandela Metropolitan University, Port Elizabeth, 
South Africa. 2Department of Infectious Diseases, Livingstone Hospital, Port Elizabeth, South Africa. 
3Department of Medicine, University of Cape Town, Cape Town, South Africa. 
 
*Corresponding Author’s E-mail: sharlene.govender@nmmu.ac.za  
 
 
Abstract 
 
Background: Pseudomonas aeruginosa is an important nosocomial pathogen that exhibits multiple drug resistance 
with increasing frequency, especially to carbapenems making patient treatment difficult. Carbapenem-resistance may 
be caused by porin gene mutations, active drug efflux, and carbapenemase production. This study evaluated the 
incidence of genes responsible for carbapenemase production in carbapenem-resistant Pseudomonas aeruginosa and 
assessed the genetic relatedness of the isolates by multi locus sequence typing (MLST).  
Materials and Methods: Identification and antimicrobial susceptibility testing of P. aeruginosa isolates (n=234) by 
the VITEK 2 system detected 81 carbapenem resistant P. aeruginosa isolates. PCR and DNA sequencing were used to 
screen isolates for three metallo-β-lactamase encoding genes. MLST included amplification of seven housekeeping 
genes and sequence type alignment using the online P. aeruginosa MLST database.  
Results: Only the blaVIM-2 gene was detected in 15 of the 81 carbapenem resistant isolates. MLST indicated six 
different novel sequence types among the blaVIM-2 positive P. aeruginosa isolates with the majority of the isolates 
(9/15) containing identical allelic profiles of the sequence type allocated ST1 (provisionally assigned sequence type, 
awaiting addition of new sequence types to PubMLST database). Five of these ST1 isolates were from patients and an 
environmental sample in the same hospital ward suggesting an environmental reservoir. Carbapenem resistance in the 
blaVIM-2 negative isolates may be due to other mechanisms.  
Conclusion: The incidence of genes responsible for carbapenemase production in carbapenem-resistant Pseudomonas 
aeruginosa and genetic relatedness of these isolates in public healthcare facilities within the Port Elizabeth area is of 
concern and requires further investigation. 
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Introduction 
 
           Pseudomonas aeruginosa is an important nosocomial pathogen that exhibits multiple drug resistance 
mechanisms with increasing frequency, especially to carbapenems making patient treatment difficult (Driscoll et al, 
2007; Hirsch and Tam, 2010). Multidrug resistant P. aeruginosa infections are mainly treated with last line β-lactam 
antibiotics, carbapenems, (Rodríguez-Martínez et al, 2009) however the overuse and misuse of carbapenem antibiotics 
has contributed to the development of carbapenem resistance in P. aeruginosa by selectively promoting the growth and 
survival of P. aeruginosa strains containing carbapenem resistant genes (Queenan and Bush, 2007; Baumgart et al, 
2010). Carbapenem-resistance may be caused by porin gene mutations, active efflux, and carbapenemase production 
(Rodríguez-Martínez et al, 2009; Nordmann et al, 2011). The mechanism depending on enzyme production is of greater 
importance due to the high level of resistance (Meletis et al, 2014). In addition, carbapenemases are encoded by genes 
located generally within mobile genetic elements, which facilitates their spread not only among strains, but also across 
species. 
A variety of molecular methods have been used to type P. aeruginosa strains (Curran et al, 2004; Gomila et al, 
2013), but these vary in their discriminatory potential. Multilocus sequence typing (MLST) is an alternative method for 
molecular typing which allows for comparison of the nucleotide sequence of a number of specific genes of different 
isolates and therefore allows for the characterization of a collection of clinical isolates (Curran et al, 2004; Belén et al, 
2009). 
Clinical P. aeruginosa isolates producing the VIM-2 carbapenemase have been reported in Cape Town and 
Port Elizabeth, South Africa (Jacobson et al, 2012; Govender et al, 2015). The objectives of this study were to evaluate 
the incidence of carbapenemase producing genes in carbapenem-resistant P. aeruginosa isolated from patients from 
public hospitals in Port Elizabeth, and to assess genetic relatedness of the isolates by MLST. 
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Materials and Methods 
Bacterial isolates 
 
P. aeruginosa isolates (n=234) were supplied by the National Health Laboratory Services (NHLS) from 
patients presenting at public hospitals in Port Elizabeth during March to August 2015. Identification and antimicrobial 
susceptibility profiles detected 81 carbapenem resistant P. aeruginosa isolates using the VITEK® 2 instrument 
(bioMérieux) (control strain: P. aeruginosa ATCC 27853) and microbroth dilution respectively. Minimum inhibitory 
concentrations (MIC) were interpreted using the Clinical and Laboratory Standards Institute interpretive criteria 
(Clinical and Laboratory Standard Institute, 2015). Permission to conduct this study was obtained from the Department 
of Health and ethics approval granted from the NMMU Research Ethics Committee [Ref: H13-SCI-BCM-008]. 
 
DNA Extraction 
 
Chromosomal and plasmid DNA were extracted from 200 μL P. aeruginosa culture using the DNeasy® blood 
and tissue and QIAprep® Spin Miniprep kits respectively, according to the manufacturer’s (Qiagen) instructions. 
Extracted DNA was quantified using the NanoDropTM Spectrophotometer (Thermo Scientific) at 260 nm. 
 
Detection of carbapenemase encoding genes 
 
Primers and PCR conditions employed for detection of the metallo-β-lactamase encoding genes (blaVIM, 
blaIMP, and blaNDM) were as previously described (Nordmann et al. 2011; Ellington et al. 2007). PCR products were 
separated in 2% (w/v) agarose gels for 45 minutes at 100 V using tris-acetate EDTA buffer [40 mM Tris base, 5 mM 
sodium acetate, 1 mM EDTA, pH 8). Ethidium bromide (Promega) stained DNA products were visualised by 
ultraviolet (UV) transillumination, and images captured using an Alpha Imager™ 3400 gel system (Alpha Innotech). 
Positive and negative controls, and a 100 bp DNA ladder (Promega) were included in each gel run to determine 
approximate sizes of the PCR products. PCR products were prepared for sequencing using a Wizard SV gel PCR clean-
up kit in accordance with the manufacturer’s instructions. Purified DNA samples were sequenced at the Central 
Analytical Facility, University of Stellenbosch. Sequence identity was then confirmed using Chromas 2.4.3 and NCBI 
BLAST. 
 
Molecular typing of isolates by MLST 
 
MLST was performed only on blaVIM positive isolates as previously outlined by Curran et al. (2004). 
Chromosomal DNA was used as a template for amplification of the seven housekeeping genes (acsA, aroE, guaA, 
mutL, nuoD, ppsA, and trpE) and the resulting PCR products were analysed by agarose gel electrophoresis and purified 
as described above. Purified DNA samples were sequenced at the Central Analytical Facility, University of 
Stellenbosch. Based on the allele sequences each isolate was assigned a sequence type number using the allelic profiles 
available on the online P. aeruginosa MLST database (PubMLST, 2015). A phylogenetic tree was constructed through 
the MEGA 6 software using the neighbour joining (NJ) method with the Kimura 2 parameter model with gamma 
correction and 1,000 bootstrap replicates for all sequences. Analyses were performed using the concatemer sequence of 
the seven sequenced genes used for the MLST assessment. 
 
Results 
 
         P. aeruginosa isolates (n=234) were recovered from urine, blood, pus, sputa and an environmental swab with the 
highest number of isolates being obtained from pus specimens. Seventy-nine isolates were resistant to carbapenems, 
with resistance to only imipenem (n=29), or both imipenem and meropenem (n=50). The blaVIM-2 negative carbapenem 
resistant P. aeruginosa isolates (n=66) were susceptible to most of the antimicrobial drugs tested when compared to the 
VIM positive isolates (refer to supplementary data). Multiple isolates were obtained from different specimens of the 
same patients.  Fifteen blaVIM-2 positive P. aeruginosa isolates were obtained from 9 different patients and one 
environmental sample in the haematology, oncology, and cardiac units.  Limited clinical information was available.  
 All VIM-2 positive carbapenem resistant isolates (100%) also showed resistance to ampicillin, amoxicillin, 
cefuroxime, cefuroxime axetil, cefoxitin, tigecycline, cefotaxime, nitrofurantoin, and trimethoprim with one isolate 
(R54) resistant to all drugs tested (Table 1).  
All VIM-2 positive carbapenem resistant isolates showed susceptibility to colistin with one exception (R54). Other than 
colistin, a number of carbapenem resistant isolates showed susceptibility to amikacin (42%), gentamicin (31%), and 
ciprofloxacin (26%) (Table 1). The MIC values for the VIM-2 positive isolates were 64 - >256 μg/mL for imipenem 
and 32 - >256 μg/mL for meropenem.  
 MLST revealed five different novel sequence types, which are not listed on the PubMLST database. These 
sequence types were provisionally allocated, ST1, ST2, ST3, ST4 and ST5 while awaiting a response after submission 
of new sequences to the PubMLST database. The majority of isolates were the sequence type allocated ST1 (Table 2).  
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Table 1: Clinical carbapenem resistant Pseudomonas aeruginosa isolates (n=15) identified as carrying the blaVIM-2 gene  
and their relevant clinical information and antibiotic susceptibility profiles 
 
Isolate No. Specimen Gender Age Resistant Intermediate Susceptible 
Health care 
Facility 
R 8 Pus Female 25 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital D 
R 22 Pus Female 34 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 27 Sputum Male 54 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, IPM, MEM, CIP, TGC, 
NIT, SXT 
CAZ, FEP AMK, GEN, CST Hospital B 
R 29 Blood Female 50 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 53a Blood Male 32 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 54a Urine Male 32 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, CST, SXT 
  Hospital A 
R 55a Urine Male 32 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital B 
R 56 Pus Female 3 AMP, AMC, CXM, CXA, FOX, CTX, IPM, MEM, TGC, NIT, SXT TZP 
CAZ, FEP, AMK, 
GEN, CIP, CST 
Hospital C 
R 70b Pus Male 57 AMP, AMC, CXM, CXA, FOX, CTX, IPM, MEM, TGC, NIT, SXT TZP 
CAZ, FEP, AMK, 
GEN, CIP, CST 
Hospital B 
R 71b Pus Male 57 AMP, AMC, CXM, CXA, FOX, CTX, IPM, MEM, TGC, NIT, SXT TZP 
CAZ, FEP, AMK, 
GEN, CIP, CST 
Hospital B 
R 85c Blood Female 49 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 88c Pus Female 49 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 89c Sputum Female 49 
AMP, AMC, CXM, CXA, FOX, CTX, CAZ, IPM, MEM, TGC, NIT, 
SXT 
TZP 
CAZ, FEP, AMK, 
GEN, CIP, CST 
Hospital A 
R 90 Environment N/A N/A 
AMP, AMC, TZP, CXM, CXA, FOX, CTX, CAZ, FEP, IPM, MEM, 
AMK, GEN, CIP, TGC, NIT, SXT 
 CST Hospital A 
R 91 Pus Male 58 AMP, AMC, CXM, CXA, FOX, CTX, IPM, MEM, TGC, NIT, SXT TZP, CAZ, FEP 
AMK, GEN, CIP, 
CST 
Hospital B 
AMP-Ampicillin; AMC-Amoxicillin-clavulanic acid; TZP-Tazobactam; CXM-Cefuroxime; CXA-Cefuroxime Axetil; FOX-Cefoxitin; CTX-Cefotaxime; 
CAZ-Ceftazidime; FEP- Cefepime; IPM-Imipinem; MEM-Meropenem; AMK-Amikacin; GEN-Gentamicin; CIP-Ciprofloxacin; TGC-Tigecycline; 
NIT-Nitrofurantoin; CST-Colistin; SXT-Trimethoprim-sulfamethoxazole 
a, b and c: refer to multiple isolates from the same patient, and includes different specimen type or different hospitals; ND: Not determined. 
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Table 2: Allelic profiles and sequence types (ST) assigned to the blaVIM positive clinical Pseudomonas aeruginosa isolates according to the PubMLST protocol and MLST 
database and corresponding carbapenem MICs of each isolate. (n=15) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a, b and c: refer to multiple isolates from the same patient, and includes different specimen type or different hospitals. 
*Provisionally assigned sequence type ST while awaiting addition of new sequence types to PubMLST database. 
Isolate acsA aroE guaA mutL nouD ppsA trpE *ST 
MIC (µg/ml) 
Imipenem Meropenem 
R 8 70 74 30 11 45 31 41 1 >256 256 
R 22 70 74 30 11 45 31 41 1 256 256 
R 27 70 74 11 21 73 135 178 2 128 128 
R 29 70 74 30 11 45 31 41 1 >256 >256 
R 53 70 74 30 11 45 31 41 1 >256 >256 
R 54a 70 74 30 11 45 31 41 1 >256 >256 
R 55a 70 74 30 11 45 31 41 1 >256 >256 
R 56a 70 74 11 21 3 4 178 3 64 32 
R 70b 70 74 30 138 45 12 3 4 128 64 
R 71b 70 74 30 138 45 12 3 4 128 64 
R 85c 70 74 30 11 45 31 41 1 >256 >256 
R 88c 70 74 30 11 45 31 41 1 >256 >256 
R 89c 99 6 39 138 3 4 178 5 256 64 
R 90 70 74 30 11 45 31 41 1 >256 >256 
R 91 99 6 39 138 3 4 178 5 >256 128 
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Multiple isolates from two patients were of the same sequence type while one patient had isolates of different sequence 
types. A dendrogram generated from the concatemer of the seven sequenced MLST genes of VIM-2 positive P. 
aeruginosa isolates (n=15) showed that with the exception of the isolate R8, the majority of the ST 1 isolates originated 
from hospital A and there was a confirmed environmental source (Figure 1). 
 
 
 
a, b, and c: refer to multiple isolates from the same patient, and includes different specimen type or different hospitals. 
 
Figure 1. Neighbour-joining dendrogram generated from the concatemer of the seven sequenced MLST genes of 
fifteen blaVIM-2 positive P. aeruginosa isolates (n=15). The scale bar (0.0005) indicates sequence divergence by the 
number of nucleotide substitutions per site. Bootstrap percentages retrieved in 1000 replications are displayed at the 
branch nodes. 
 
Discussion 
 
 The emergence of multidrug resistant nosocomial bacteria has become a world-wide concern, especially with 
the emergence of resistance to last line antibiotics such as carbapenems. In this study, 35% (81/234) of P. aeruginosa 
isolates exhibited resistance to carbapenems with 12% (29/234) resistant to only imipenem and 23% (52/234) to both 
imipenem and meropenem. It is known that meropenem is more resistant than imipenem to enzymatic hydrolysis due to 
the 1-β-methyl group it contains within its structure (Shah and Isaacs, 2003). Similar findings were reported in Spain 
with carbapenem resistance in 39% (175/448) of clinical P. aeruginosa isolates (Riera et al, 2011). 
 The MIC values of the blaVIM positive isolates were 64 - >256 μg/mL for imipenem and 32 - >256 μg/mL 
for meropenem while MIC values were ≥8 μg/mL for blaVIM negative isolates. This exceeded the 8 μg/mL 
breakpoints recommended by both the EUCAST and CLSI guidelines for imipenem and meropenem resistance. MIC 
values >32 ug/ml and >256 μg/mL have been documented for imipenem and meropenem of carbapenemase producing 
P. aeruginosa by other researchers (Riera et al, 2011; Cho et al, 2015; Edelstein et al, 2013). 
 The metallo-β-lactamase VIM-2 encoding gene, blaVIM-2, was found in 15 carbapenem resistant P. 
aeruginosa isolates. The production of carbapenemases is known to be one of the major mechanisms involved in 
carbapenem resistance (Rodríguez-Martínez et al, 2009). However it must be noted that only 15 of 81 carbapenem 
resistant P. aeruginosa contained the blaVIM-2 gene. Carbapenem resistance in the blaVIM-2 negative isolates is most 
likely due to other mechanisms such as active drug efflux pumps and porin gene mutations (Rodríguez-Martínez et al, 
2009). It is also possible that other classes of carbapenemases rarely found in P. aeruginosa may have been present 
which were not screened for in this study. Cho et al, (2015) reported that of 61 carbapenem resistant P. aeruginosa 
isolates, obtained from a tertiary hospital in Daejeon, Korea, 25 (41%) were metallo-β-lactamase producers. Cho et al, 
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(2015) screened the isolates for 27 different β-lactamase encoding genes, but it was only VIM and IMP metallo-β-
lactamases that were found within the P. aeruginosa isolates. Interestingly Cho et al (2015) reported that in each VIM 
and IMP positive isolate OXA-type carbapenemases were also present.  
 This study screened for the most common carbapenemases present in P. aeruginosa, hence future research 
could include detection of other carbapenemases. However, OXA-23 and OXA-51 carbapenemases have been reported 
in clinical P. aeruginosa isolates in Port Elizabeth (Gqunta, 2014). Riera et al, (2011) reported VIM-2, VIM-13 and 
VIM-20 as being the only metallo-β-lactamases found in the isolates screened at a hospital in Spain. 
 The MLST method of molecular typing for P. aeruginosa was used and it assesses the sequence of seven 
highly conserved housekeeping genes (acsA, aroE, gauA, mutL, nuoD, ppsA, and trpE) and by comparing the 
sequence and combination of genes the clonal relationship between isolates can be assessed (Curran et al, 2004). It has 
been reported that isolates with the same sequence types (ST) can be considered as members of the same clone, and P. 
aeruginosa isolates that share at least five of the seven numbers within their allelic profile were regarded as members 
of the same clonal complex (PubMLST, 2015; Tiexeira and Merquior, 2013). Figure 1 illustrates that when 
phylogenetic analysis was applied using the concatemer of the seven sequenced MLST genes, isolates exhibiting the 
same sequence type all clustered together within the phylogenetic tree. This indicates a high likelihood of isolate 
relation and supports the sequence types applied to the P. aeruginosa isolates through the MLST protocol. It can also 
be seen that isolates of different sequence types differ greatly from each other within figure 1, which is expected. 
 Isolates R8, R22, R29, R43, R53, R54, R55, R85, R88, and R90 (unique sequence type allocated ST1) share 
identical allelic profiles and sequence types as determined by MLST. However, these are unique sequence types which 
have not been listed on the PubMLST database. Mudau et al (2013) conducted a study in Cape Town, South Africa, 
where the MLST protocol was utilized to type clinical P. aeruginosa isolates. When compared to the results of this 
study, a few similar allelic numbers were seen namely; mutL: 11, ppsA: 31, and trpE: 41. However there is diversity in 
the allelic profiles and sequence types of the isolates from Port Elizabeth and Cape Town studies (Mudau et al, 2013). 
 While the majority of the isolates were ST1 (60%), these isolates were largely confined to the outbreak in 
Hospital A, spread via an environmental reservoir (R90), with only one other ST1 isolate (R8) being identified outside 
of hospital A.  Furthermore, three P. aeruginosa isolates (R53, R55 and R56) from the same patient were of the same 
sequence type (ST1) and it should be noted that this patient was transferred from hospital A to hospital B. Another 
patient from hospital A was found to harbour two P. aeruginosa isolates (i.e R88 and R89) of different sequence types 
(ST1 and ST5 respectively). The source of the ST5 isolate in this patient is unknown.   
 Although it is acknowledged that there are limitations in the sample size and available clinical information, the 
diverse sequence types in the different hospitals highlights the occurrence of widespread carbapenem resistant P. 
aeruginosa isolates. Hospital B is the referral hospital and had four different sequence types, implying multiple 
introductions of the carbapenem resistant P. aeruginosa isolates which may be indicative of a more pervasive problem. 
The incidence of genes responsible for carbapenemase production in carbapenem-resistant Pseudomonas aeruginosa 
and genetic relatedness of these isolates in public healthcare facilities within the Port Elizabeth area is of concern and 
requires further investigation. 
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